Coloplast's important growth market still curbed by the pandemic

China is a key part of the medtech company’s growth plan for its ostomy business, but extensive Covid-19 restrictions are hampering growth. ”We don’t predict any improvements this calendar year,” says CFO Anders Lonning-Skovgaard.

Anders Lonning-Skovgaard, CFO of Coloplast | Photo: Niels Hougaard/ERH

Although Coloplast has geared back up after the pandemic, reporting 8% organic growth and an operating margin of 30% before special items in the latest quarter, one thing in particular is slowing the medtech company down.

Coloplast’s ostomy business, dubbed Ostomy Care, has been strongly impacted by lockdowns in China.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs